Recent News

• 02.20.2026 - Ernexa Therapeutics to Participate in Virtual Investor Closing Bell Series
• 02.06.2026 - Ernexa Therapeutics Announces Pricing of $10.5 Million Public Offering
• 02.03.2026 - Ernexa Therapeutics Participates in Virtual Investor “What This Means” Segment Highlighting Recent Successful Pre-IND Meeting with U.S. FDA
• 01.27.2026 - Ernexa Therapeutics Selected as One of Only Ten Global Companies for Prestigious JETRO Japan Entry Acceleration Program
• 01.06.2026 - Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer

Recent Filings

• 02.17.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.17.2026 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 02.11.2026 - EX-99.1 EX-99.1
• 02.11.2026 - 8-K Current report
• 02.10.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.05.2026 - 8-A12B Registration of securities [Section 12(b)]
• 02.05.2026 - CERT Certification by an exchange approving securities for listing
• 02.05.2026 - S-1/A General form for registration of securities under the Securities Act of 1933
• 02.05.2026 - EFFECT Notice of Effectiveness
• 02.04.2026 - S-1/A General form for registration of securities under the Securities Act of 1933